Cancer Therapy Gets a Little PersonalApril 14, 2015Just like snowflakes we are all unique (at least genetically speaking), and unfortunately for modern medicine so are our cancers. This individuality in cancers, even of the same type or subtype, means that there is no single cure-all. However, researchers, like those at the from Washington University in St. Louis and The University of Oklahoma, […]
Bees Model Their Potential for Epigenomic ResearchApril 13, 2015With spring in the air, the honeybees are already out and buzzing about and now an international team from Australia and Poland have created a different type of buzz with their research into 5hmC and its effect of bee’s behaviour. The importance of epigenetics in bees has already been suggested with the finding that honeybees use miRNAs to enable their […]
The Little Blue Pill Gets an Optogenetic UpgradeApril 13, 2015While there’s no denying that optogenetics is one stimulating piece of biotechnology, the double entendre of optogenetics being a ‘turn on‘ has now become fact. The lab of Martin Fussenegger at ETH Zurich’s Department of Biosystems in Basel, Switzerland has developed a synthetic optogenetic technology that allows for the blue Viagra® pill to be skipped by a blue light that induces penile […]
CRISPR Gets Creative with Histone AcetylationApril 9, 2015There’s been a lot of firsts in the world of genome editing happening lately, from its application in human embryonic stem cells, the identification of a smaller more versatile Cas9, to its upgrade to efficiently using homology-directed repair. Now CRISPR-Cas9 is getting its feet wet with epigenome editing thanks to the clever folks in the Gersbach lab […]
Slimmer Cas9 is Better Able to Squeeze into CellsApril 7, 2015We’ve already seen how CRISPR-Cas9 is making the headlines with its utility in human embryonic stem cell editing, but now it’s getting a makeover to make it even more attractive for use in humans. Current CRISPR-Cas9 genome editing technology is faced by two translational limitations. The first is targeting, where PAM sequences and sgRNA design […]
